Condor Capital Management’s Eucrates Biomedical Acquisition Corp. Unit EUCRU Stock Holding History

Condor Capital Management’s Portfolio EUCRU Stock Details EUCRU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,600	Closed	-$26K	–	390
2022 Q3	$26K	Buy	2,600 +800	+44%	+$7.97K	﹤0.01%	350
2022 Q2	$18K	Sell	1,800 -800	-31%	-$7.94K	﹤0.01%	371
2022 Q1	$26K	Hold	2,600	–	–	﹤0.01%	315
2021 Q4	$26K	Hold	2,600	–	–	﹤0.01%	284
2021 Q3	$26K	Hold	2,600	–	–	﹤0.01%	250
2021 Q2	$27K	Hold	2,600	–	–	﹤0.01%	247
2021 Q1	$26K	Buy	+2,600	New	+$27.7K	﹤0.01%	240

Other funds holding EUCRU

Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Condor Capital Management's EUCRU Position: Q4 2022 in Review

Condor Capital Management sold out of Eucrates Biomedical Acquisition Corp. Unit (EUCRU) in Q4 2022, closing a stake of 2,600 shares — an estimated $26K sold.

Condor Capital Management first reported a position in EUCRU in Q1 2021 and held it in 7 quarters. The position peaked at $27K in Q2 2021. 6 funds tracked by Wall St. Rank hold EUCRU as of Q4 2022.

Condor Capital Management reported no remaining Eucrates Biomedical Acquisition Corp. Unit position as of Q4 2022 after selling out during the quarter.
Condor Capital Management sold 2,600 Eucrates Biomedical Acquisition Corp. Unit shares in Q4 2022, an estimated $26K.
Condor Capital Management first reported a position in Eucrates Biomedical Acquisition Corp. Unit in Q1 2021 and held it in 7 quarters.
Condor Capital Management's Eucrates Biomedical Acquisition Corp. Unit position peaked at $27K in Q2 2021.
6 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Unit as of Q4 2022.

Based on Condor Capital Management's 13F filing for Q4 2022, filed 7 Feb 2023.